You just read:

MabVax Therapeutics Nominates The Fully Human Antibody HuMab 5B1 As The Company's Lead Clinical Development Candidate

News provided by

MabVax Therapeutics Holdings, Inc.

Oct 21, 2014, 09:00 ET